Received Apr 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | KD27Z | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | AZ2A3 | — |
Early third dose; Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 28-year-old female patient who received HAB (Twinrix) (batch number KD27Z) for prophylaxis. Co-suspect products included HAB (Twinrix) (batch number AZ2A3, expiry date 05-FEB-2028) for prophylaxis. Previously administered products included Twinrix (received first dose on 24-SEP-2025 with batch number AZ2A3 and expiry 05-FEB-2028). On 26-MAR-2026, the patient received the 3rd dose of Twinrix. On 19-NOV-2025, the patient received the 2nd dose of Twinrix. On 19-NOV-2025, not applicable after receiving Twinrix and an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). On 26-MAR-2026, the patient experienced drug dose administration interval too short (Verbatim: Early third dose). The outcome of the drug dose administration interval too long and drug dose administration interval too short were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 31-MAR-2026 On 31-MAR-2026 a pharmacist called to report that a patient received Twinrix as follows first dose on 24-SEP-2025, second dose on 19-NOV-2025, and third dose on 26-MAR-2026. The expiration date for the third dose was not provided. No further details were provided.